CD274 and neoplasm: The results showed that the monotherapy of bufalin or PD‐L1 antibody stalled tumor growth, volume, and weight in a dose‐dependent manner, whereas the mixed strategy exhibited more powerful tumor suppression compared to monotherapy with either agent (Figure 6F,G).